![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, May 21, 2024 5:36:57 PM
BioElectronics Corporation Announces Utility Patent Application Filing
FREDERICK, MD - ( NewMediaWire ) - May 21, 2024 - BioElectronics Corporation ( https://www.bielcorp.com/ OTC: BIEL a developer of medical technology products, today announces the filing of a new USPTO utility patent application addressing the treatment of chronic inflammation. This patent application, numbered 18/667,971, was a collaborative effort of John Martinez, Kenneth McLeod, PhD, and Richard Staelin, PhD. It outlines methods, systems, apparatuses, and devices that modify the immune response through non-invasive stimulation of the vagal nerves. The application draws from the results of a recently completed double-blind, placebo-controlled, canine study, published in Veterinary Medicine and Science which demonstrated that Pulsed Short Wave Therapy (PSWT) Technology applied to the vagal nerves of dogs diagnosed with osteoarthritis resulted in significant reductions in systemic discomfort.
Chronic inflammation poses a significant challenge to modern medicine. While few effective interventions exist, management of the condition often involves removing inflammatory triggers through dietary or lifestyle changes. Additionally, anti-inflammatory medications are commonly used, but their chronic use is costly and associated with significant side effects.
A promising approach for addressing chronic inflammation emerged with the discovery of the inflammatory reflex. Similar to reflexes in the somatic nervous system, this reflex involves both the afferent (incoming) and efferent (outgoing) arms of the vagus nerve. Although vagus nerve stimulation has been shown to suppress pro-inflammatory cytokine levels in the periphery, traditional stimulation techniques are not suitable for chronic vagus nerve stimulation.
BioElectronics’ PSWT technology and device designs overcome this limitation, providing a convenient, economical, and highly effective alternative for treating chronic inflammation. Given that over one-third of Americans suffer from chronic, systemic inflammation, this development opens an enormous new market opportunity for BioElectronics. The company plans to continue its efforts to provide clinical support and develop new designs for its product line.
FEATURED Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM